Clinical trials: Autoimmune Disorder
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Arthritis, Rheumatoid
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
The main objective of this trial is to provide long-term safety, pharmacokinetics (PK), and immunogenicity data on BI 695501 administered via prefilled syringe in patients with Rheumatoid Arthritis who have completed Trial…
- Trial name
- NCT02640612
- Testing
- BI 695501
- Where
- 91 sites in United States, Bulgaria and 12 more
- Volunteers
- 430 people
- Sponsor
- Boehringer Ingelheim
Lupus Nephritis
A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis
This study will compare the efficacy of CellCept [0.5-2 grams per day (g/day) orally (p.o.)] and cyclophosphamide [0.5-1 grams per square meter (g/m2) quarterly] as maintenance treatment for patients with lupus nephritis.
- Trial name
- NCT02081183
- Testing
- Mycophenolate mofetil (MMF), Cyclophosphamide, Maintenance Phase, Cyclophosphamide, Induction Phase
- Where
- 2 sites in Venezuela
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Dawn Phenomenon
Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
1. To investigate the effect of insulin glargine (Lantus™) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes. 2.
- Trial name
- DAWN (NCT00694122)
- Testing
- Lantus (glargine)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Graft-Versus-Host Disease
Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease
This study is designed to collect longitudinal biological samples from patients after hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers to validate biomarkers of both acute and chronic…
- Trial name
- NCT02194439
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Indiana University
Rheumatoid Arthritis
PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
Patients with rheumatoid arthritis have a significantly higher risk to develop heart attacks and other complications of their blood vessels. New therapies are needed to prevent this complication.
- Trial name
- RAPPAR (NCT00554853)
- Testing
- pioglitazone, Sublingual nitroglycerine
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- University of Michigan
Type 1 Diabetes Mellitus
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT02044848
- Testing
- Secukinumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Psoriatic Arthritis
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- ProAct (NCT01078558)
- Volunteers
- 5,940 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Rheumatoid Arthritis
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.
- Trial name
- RA-BEYOND (NCT01885078)
- Testing
- Baricitinib
- Where
- 408 sites in United States, Argentina and 36 more
- Volunteers
- 2,877 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
This randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (MTX) versus maintaining MTX dosage in patients with severe active rheumatoid arthritis and an inadequate…
- Trial name
- NCT01661140
- Testing
- Methotrexate (stable dose), Tocilizumab, Methotrexate (tapering dose)
- Where
- 67 sites in United Kingdom
- Volunteers
- 427 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol when administered without coadministration of methotrexate over the long term in Japanese RA patients who transferred from Study…
- Trial name
- NCT00850343
- Testing
- Certolizumab pegol
- Where
- 8 sites in Japan
- Volunteers
- 208 people
- Sponsor
- Astellas Pharma Inc
Type 1 Diabetes Mellitus
Siplizumab in T1DM
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0.
- Trial name
- DESIGNATE (NCT05574335)
- Testing
- Siplizumab
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Short Term: The purpose of this clinical research study is to learn if abatacept (BMS-188667) in combination with methotrexate is better than methotrexate alone in participants that have active rheumatoid arthritis and are not…
- Trial name
- NCT00048568
- Testing
- Abatacept, Methotrexate
- Where
- 48 sites in United States
- Volunteers
- 1,250 people
- Sponsor
- Bristol-Myers Squibb
Type 1 Diabetes
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms
Objective: to gain experience with in-home use of a modified algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is projected overnight and to obtain…
- Trial name
- PHM2 (NCT02438189)
- Testing
- Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm
- Where
- 3 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Jaeb Center for Health Research
Cannabis Use Disorder, Multiple Sclerosis
A Teleheath tDCS Approach to Decrease Cannabis Use
The study aims to evaluate the effect of Dorsolateral Prefrontal Cortex (DLPFC) Transcranial Direct Current Stimulation (tDCS) in decreasing distress and cannabis use.
- Trial name
- NCT05005013
- Testing
- Transcranial Direct Current Stimulation (tDCS), Mindfulness
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- NYU Langone Health
Diabetes Mellitus, Type 1 Diabetes
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a challenging medical disorder, especially in children and adolescents. In order to prevent the chronic complications of hyperglycemia, the maintenance of near-normal glycemic control must be…
- Trial name
- NCT04157738
- Testing
- Rapid-Acting Insulin, Long acting insulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 1
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM
The purpose of this study is to determine the efficacy, tolerability, safety, and effect on quality of life of CGM in children 4 to less than 10 years of age with type 1 diabetes.
- Trial name
- NCT00760526
- Testing
- Continuous glucose monitor, Home blood glucose monitor
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- Jaeb Center for Health Research
Rheumatoid Arthritis (RA)
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT03823378
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 30 sites in Belgium, Canada and 5 more
- Volunteers
- 97 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.